About Us

Our vision... is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs...

GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.


GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange (GWP). The company is developing a product portfolio of cannabinoid prescription medicines, including Sativex. GW occupies a world-leading position in cannabinoid science.... Read more on our overview here


GW’s focus is to develop novel prescription medicines which make a real difference to the lives of patients.